Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 14, 2010
Event Date: July 5, 2010 (Agreement Execution)
Context: The filing reports the entry into a material definitive agreement by Oramed Ltd., a subsidiary of Oramed Pharmaceuticals Inc., to secure supply for clinical trials.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Manufacturing Supply Agreement (MSA): On July 5, 2010, Oramed Ltd. entered into an MSA with SANOFI-AVENTIS DEUTSCHLAND GMBH ("sanofi-aventis").
Scope: Sanofi-aventis will supply specified quantities of recombinant human insulin.
Purpose: The insulin is designated for use by Oramed in its clinical trials conducted in the USA.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on July 7, 2010, announcing the transaction (incorporated as Exhibit 99.1).
Risks and Contingencies: The filing states that the description of the MSA is not complete and is qualified in its entirety by reference to the actual transaction document (Exhibit 10.1). No specific financial risks or forward-looking guidance regarding revenue or timelines are detailed in the summary text of this filing.
Investor Verification Checklist
- Review the full text of the Manufacturing Supply Agreement (Exhibit 10.1) to understand pricing, volume commitments, and termination clauses.
- Verify the specific quantities of recombinant human insulin agreed upon for the USA clinical trials.
- Confirm the impact of this supply agreement on the timeline of Oramed's clinical trial phases.
- Check the press release (Exhibit 99.1) for additional context not included in the 8-K summary.